About Oxurion NV

Company Description

Oxurion is on a mission to transform the treatment of retinal disorders, including the development of THR-149, its novel therapeutic for the treatment of DME.

Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people worldwide.

Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.

Year founded


Served area



Gaston Geenslaan 1, 3001 Leuven, Vlaams-Brabant – Belgium

Shareholder information

Shares outstanding



July 7, 2006

Stock exchange(s)

Euronext Brussels



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.